- Home
- DRIO vs MBRX Comparison
DRIO vs MBRX Comparison
Compare DRIO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- MBRX
- Stock Information
- Founded
- DRIO 2011
- MBRX 2015
- Country
- DRIO United States
- MBRX United States
- Employees
- DRIO N/A
- MBRX N/A
- Industry
- DRIO Medical/Dental Instruments
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- DRIO Health Care
- MBRX Health Care
- Exchange
- DRIO Nasdaq
- MBRX Nasdaq
- Market Cap
- DRIO 21.9M
- MBRX 24.3M
- IPO Year
- DRIO N/A
- MBRX 2016
- Fundamental
- Price
- DRIO $15.20
- MBRX $0.48
- Analyst Decision
- DRIO Strong Buy
- MBRX Strong Buy
- Analyst Count
- DRIO 2
- MBRX 4
- Target Price
- DRIO $50.00
- MBRX $5.00
- AVG Volume (30 Days)
- DRIO 152.1K
- MBRX 2.8M
- Earning Date
- DRIO 11-06-2025
- MBRX 11-07-2025
- Dividend Yield
- DRIO N/A
- MBRX N/A
- EPS Growth
- DRIO N/A
- MBRX N/A
- EPS
- DRIO N/A
- MBRX N/A
- Revenue
- DRIO $27,148,000.00
- MBRX N/A
- Revenue This Year
- DRIO N/A
- MBRX N/A
- Revenue Next Year
- DRIO $62.31
- MBRX N/A
- P/E Ratio
- DRIO N/A
- MBRX N/A
- Revenue Growth
- DRIO 41.79
- MBRX N/A
- 52 Week Low
- DRIO $5.94
- MBRX $0.25
- 52 Week High
- DRIO $31.00
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- DRIO 69.20
- MBRX 53.68
- Support Level
- DRIO $15.01
- MBRX $0.42
- Resistance Level
- DRIO $17.74
- MBRX $0.55
- Average True Range (ATR)
- DRIO 1.81
- MBRX 0.04
- MACD
- DRIO 0.27
- MBRX 0.01
- Stochastic Oscillator
- DRIO 78.40
- MBRX 59.68
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.